Anyone know of any company that had less than 12 months of cash on hand that got a good deal for a ph ii compound…?
Reata’s $450M deal with ABT for Bardoxolone (#msg-54747777) may qualify, although Reata’s pre-deal financial status isn’t precisely known because the company is private.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”